



## FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

August 07, 2020

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051

Scrip Code: 531599

Symbol: FDC

**Sub.: Press Release**

Dear Sir / Madam,

Please find attached herewith the Press Release issued in relation to the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30<sup>th</sup> June,2020.

Kindly take the same on record.

Thanking you,

Yours truly,  
For FDC LIMITED

  
Varsbarani Katre  
Company Secretary  
F-8948



CORPORATE OFFICE

142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA  
Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 • Fax +91-22-2677 3462  
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE

B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA  
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299  
E-mail waluj@fdcindia.com • CIN L24239MH1940PLC003176



**FDC Limited**

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS



## FDC Limited reports Q1FY21 results

Mumbai, 07 August 2020: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the first quarter ending 30<sup>th</sup> June, 2020.

### Consolidated Q1 FY21 FDC reported

Rs. in Crores	Q1' 20-21	Q1' 19-20	YoY Growth
Operating Revenues	308.18	343.52	-10.29%
EBITDA	131.55	88.26	49.05%
EBITDA %	42.69	25.69	
PBT	121.36	78.09	55.41%
PAT	91.72	56.22	63.14%
EPS	5.36	3.22	66.46%

### Commenting on the results;

The Q1 performance reflects the impact of the global COVID-19 pandemic and consequent lockdown across markets and is not an indicator of the underlying strength of our business. Our timely risk mitigation initiatives ensured smooth operations of our manufacturing network, thereby maintaining continuous supplies of drugs. In the meantime, we continue to focus on serving our patients and customers, ensuring safety of our employees and business continuity.

We saw the impact of Covid situation and lockdown in the domestic market, while trying to do better in the Domestic market, we have emphasized more on delivering Export orders and preponed the production schedule wherever possible. And worked on reducing/controlling costs.

### India Market:

Sale of branded formulations in India for Q1FY21 was Rs. 231.43 crores, a decline of 13.66% over the same quarter last year. Overall sales in India markets accounted for 75.67% of total consolidated sales for the quarter.

FDC has believed in providing quality products at affordable prices. So, to fight Coronavirus and help the society, FDC is planning to launch Favipiravir for the treatment of mild to moderate cases of Covid-19 in India.



CORPORATE OFFICE

: 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA  
Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2677 3462  
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE

: B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA  
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299  
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176

## **Export Formulations Market:**

Formulation Sales in the Export market were Rs. 59.26 crores in Q1FY21, a decline of 3.01% over Q1 last year and accounted for 19.34% of total consolidated sales.

The main contributor is the USA market, accounting to 74.72 % of total Export Formulations Sales. FDC is planning to launch Olopatadine ophthalmic solution 0.1% in the USA market for increasing presence in Ophthalmic Therapy. 1 ANDA to be filed this year apart from 7 approved ANDA's, all in Ophthalmics.

## **Export API Market:**

API Sales in the Export market were Rs. 15.28 crores in Q1FY21, a increase of 36.36 % over Q1 last year and accounted for 4.99 % of total consolidated sales. We are focusing on increasing the Export API sales in the coming year.

## **ABOUT FDC LTD**

Established in 1940, with the dream of building a world class company and vision to make the nation self-reliant in healthcare. FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE, to cite a few. FDC is a forerunner in manufacturing and marketing of Oral Rehydration Salts (ORS) and Ophthalmics. FDC has also set-up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life to millions globally.

## **Disclaimer**

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

